Pharmacogenomics of cancer therapy-related cardiomyopathy in childhood cancer survivors.
Despite progress, barriers to clinical implementation remain, including heterogeneous phenotype definitions, limited replication, especially in non-European populations, and lack of prospectively validated risk models remain.